Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

The Prognostic Value of G1 Cyclins, p21 and Rb Protein in Patients With Colon Cancer

PANTELIS PALAIOLOGOS, DIMOSTHENIS CHRYSIKOS, STAMATIOS THEOCHARIS and GREGORY KOURAKLIS
Anticancer Research November 2019, 39 (11) 6291-6297; DOI: https://doi.org/10.21873/anticanres.13839
PANTELIS PALAIOLOGOS
12nd Department of Propedeutic Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIMOSTHENIS CHRYSIKOS
2University Department of Surgery, General and Oncologic Hospital of Kifissia ‘Agii Anargiri’, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dixrys@yahoo.gr
STAMATIOS THEOCHARIS
3First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GREGORY KOURAKLIS
12nd Department of Propedeutic Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Cyclins D1 and E play different roles in the cell cycle. Cyclin E promotes chromosome instability, whereas cyclin D1 regulates apoptosis of cells. This study evaluated the prognostic significance of G1 cyclins, p21 and pRb in tumor proliferation. Patients and Methods: A total of 102 patients with colon cancer were operated on and staged according to TNM. Follow-up was 2 to 68 months (mean 38.3±16.7 months). Expression of cyclin E and D1 were evaluated using immunohistochemistry. Results: Levels of cyclin E expression were correlated with cyclin D1 expression (p=0.038), p21 expression (p=0.047), and pRb expression (p=0.004). The 5-year survival rate along with prognosis of patients with advanced stage (III, IV) colon cancer and cyclin D1 positive tumors, were significantly worse (p=0.009). Statistically significant association was observed between tumor proliferative capacity Ki-67, cyclin D1 (p=0.009), pRb (p=0.031) and p21 (p=0.050). Conclusion: Cyclin D1 is highly expressed in advanced stage colon cancer patients, implying a potential prognostic value.

  • Cyclin D1
  • cyclin E
  • Rb
  • p21
  • prognosis
  • colon cancer

Colorectal cancer (CRC) is one of the main challenges for public health representing the third most common cancer worldwide, following prostate and lung cancer in males and breast and lung cancer in females (1, 2). According to the World Health Organization, in 2018 there were 1.8 million colorectal cancer cases of which 861,000 resulted in death (3). In the United States, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in 2019 (4). The annual estimation of new cases diagnosed with large bowel cancer is approximately 145,600 (4). Among these, 101,420 are colon and the remainder are rectal cancers, while CRC-related deaths are approximately 50,630.

Currently, advances in chemotherapy either as adjuvant in colon cancer, or as neoadjuvant with radiotherapy in rectal cancer, require the precise determination of the subgroup of patients which may have a survival benefit (5). In this respect, the identification of specific, early expressed biomarkers may contribute to a better prognosis of patients with intermediate grade tumors.

Cyclins and the cyclin-dependent kinases, are key regulators of the cell cycle (6). Errors in the normal process of the cell cycle result in deregulated DNA replication and mitosis (7) leading to increased resistance to apoptosis and the induction of cancer (8, 9). A major cell cycle regulatory point in most animal cells called the restriction point, occurs late in G1 and controls progression from G1 to S (10). The two main aspects of cell cycle regulation are the DNA structure checkpoints, which arrest the cell cycle in response to DNA damage or incomplete replication, and the existence of the restriction point (11). Once cells have passed the restriction point, they are normally committed to proceed and divide, hence, the so called G1 cyclins have a prevailing role in promoting cell division (12). The G1-S transition of the cell cycle, is mainly regulated by cyclins D1 and E, each of them playing a different and discrete role (13). Cyclin E has been involved in various cancer cell lines (14), in breast carcinomas (15) and in about 10% of colorectal cancer cases (16). Keyomarsi et al., (1994) reported a correlation between cyclin E expression and advanced stage breast carcinomas, implying its potential role as a prognostic marker (17).

The retinoblastoma (Rb) protein is a tumor suppressor, and a key negative regulator of the cell cycle (18) by suppressing G1 phase progression (19). Rb protein is active in the early G1 phase in its hypophosphorylated form, whereas in mid/late G1 phase the protein becomes inactivated by phosphorylation. Cyclins D1 and E, along with their catalytic partners, the cyclin-dependent kinases (cdk), are responsible for this phosphorylation of pRb and also regulate progression of the cell cycle from G1 to S-phase (20). Moreover, p21 acts by binding cdks in the G1 phase of the cell cycle and leading to the inhibition of phosphorylation of other proteins like Rb, necessary for cell cycle progression (21). The protein product of Rb leads to the inhibition of the cyclin D1 and cyclin E promoter activity by binding to E2F transcription factors. In mid-to-late G1 phase, where Rb is initially phosphorylated, probably by cdk-cyclin D complexes, E2F transcription factors are produced, which promote transcription of the cyclin D1 and cyclin E genes (22-24). Inactivation of the Rb gene is involved in various types of cancers (25, 26), however in colorectal carcinomas loss or inactivation of Rb seems to be rare (27). In contrast to the fact that loss of pRb activity is observed in various tumors, other studies have depicted increased levels of Rb transcripts in colorectal cancer, implying a potential mitotic role of pRb (28, 29). Moreover, increased cyclin D1 and cyclin E expression endures Rb phosphorylation. As a consequence, additional E2Fs are released that pursue cyclin D1 and cyclin E transcription. Overexpression of cyclin D1 or cyclin E enhances phosphorylation of Rb and promotes cellular proliferation suppressing pRb activity. This concept of cyclin D1 and cyclin E as positive regulators of cell proliferation is supported by various studies where microinjection of anti-cyclin D1 and E antibodies prevent cells from entering the S-phase of the cell cycle (30-32).

Overexpression of cyclin D1 or cyclin E is positively involved in carcinogenesis as increased levels of cyclin D1 and E have been shown to induce cell growth by shortening the duration of the G1 phase of the cell cycle (13, 32). Mermelshtein et al. reported a correlation between cyclins D1 and/or D2, but not cyclin D3, and TNM stage of colon carcinomas. In addition, overexpression of cyclin D2 may be strongly related to a higher TNM stage of tumors (33). In another prospective patient cohort study by Wangefjord et al., it was depicted that cyclin D1 expression in colorectal cancer has a different effect in males and females. It was shown that cyclin D1 was a favorable prognostic factor in men compared to women (34). A meta-analysis in 2014, of 22 studies and a total of 4150 patients, indicated that cyclin D1 is an unfavorable prognostic factor for colorectal cancer. Cyclin D1 overexpression might be associated with a poor clinical outcome and clinical and pathological data such as age, tumor, lymph nodes and distant metastasis in colorectal cancer patients (35). Al-Maghrabi J et al. have also published that expression of cyclin D1 in colorectal carcinomas is not related to overall survival. No significant correlation with clinicopathological features was presented, except from lympho-vascular invasion (36).

We can assume that overexpression of cyclins, may not only contribute to tumorigenesis but may also have a potentially predictive role in the clinical aggressiveness of colon carcinomas. In the present study, we investigated immunohistochemically the expression of both G1 cyclins (D1 and E) in relation to Ki-67 expression, in human colon cancer specimens. The above data support that cyclins may be used as sensitive and accurate markers in the diagnosis of colorectal cancer (37). The present study aimed to identify the involvement of G1 cyclins in the cell cycle regulation of human colon cancer cells and whether there is any prognostic significance in subgroups of patients, according to staging.

Patients and Methods

Study population. The study group consisted of 102 patients with newly diagnosed and histologically confirmed colon cancer, 60 men (58.8%) and 42 (41.2%) women. All patients enrolled, received surgical resection treatment with curative intent. The age composition of our study population was 42-94 years with a mean age of 70.6 years. Patients with rectal cancer and those who refused follow-up were excluded from the study.

Histology and immunohistochemistry. Histology: Tissue samples were fixed in 10% formalin and embedded in paraffin A. Five μm thick paraffin sections were produced using a microtome. Dewaxed sections were stained with hematoxylin and eosin as previously described (38).

Immunocytochemistry: Sections were incubated in 10 mM citrate buffer (pH 6.0) for 15 min, and then exposed to freshly prepared 0.3% hydrogen peroxide in methanol, for 30 min, at room temperature (RT). Blocking was performed using blocking reagents (Snipper, Biocare Biochemicals, Walnut Creek, CA, USA), for 10 min. Sections were incubated for 1 h, at RT, with the primary antibodies diluted in 1:100 phosphate buffered saline (PBS). Slides were the incubated with secondary biotinylated antibodies for 20 min at RT. Peroxidase-streptavidin labelling (AB Complex, Dakopatts) was performed for 20 min, at RT. Then, the colour was developed in 0.5% (v/v) 3.3’-diaminobenzidine hydrochloride (DAB, Sigma, St Louis, MO, USA) in PBS containing 0.03% (v/v) hydrogen peroxide for 2 min. Antigens were retrieved only for Ki-67, by the use of microwaves. All immunohistochemical studies were blinded to the clinical data. The primary antibodies used were: mouse (IgG1k) monoclonal antibodies anti-cyclins D1 and E (Santa Cruz Biochemicals, CA, USA), anti-human pRb (Santa Cruz Biochemicals), and anti-Ki-67 (Dakopatts, Glostrup, Denmark). Secondary antibodies included the Rodent immunoglobulins (Dakopatts) for detection of cyclin D1, cyclin E and Ki-67 and the swine anti-rabbit immunoglobulins for pRb, and were diluted 1:200 in PBS.

Statistical analysis. We evaluated the correlation between cyclin E, cyclin D1, p21, pRb and Ki-67 expression and various clinical and pathological variables (age, location, stage and grade, lymph node metastasis, liver metastasis and vascular invasion) by using the chi-square test (X2). Kaplan–Meier survival curves were compared using the log rank test. The effect of each potential prognostic factor on patients' overall survival was evaluated by using Cox regression analysis. Results were considered statistically significant when p-value was less than 0.05 (p<0.05).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Section of a colon cancer specimen stained positive for Cyclin E. Magnification: ×20

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Section of a colon cancer specimen stained positive for pRb. Magnification: ×20

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

The expression of cyclins D1, E, p21 and their correlation to clinical and pathologic characteristics of colon cancer (X2 test).

Results

Patients tumor, node, metastasis (TNM) staging classification. The total of 102 patients included in this study had been diagnosed with colon cancer. None of the patients had received any preoperative chemotherapy. Anatomic subsites of tumors were located in the right, cecum and the ascending colon in 28 cases (27.5%), in the transverse colon in 7 cases (6.9%), in the descending colon in 9 cases (8.8%) and in the sigmoid in 58 cases (56.8%). Patients were operated with an open or laparoscopic technique and the collected tumor samples were histopathologically staged according to the 6th edition of the TNM classification system as: T1-2N0, 16 cases (15.7%); T3-4N0, 39 cases (38,2%); T1-4 N1-2, 24 cases (23.5%); and T1-T4 N0-2M1, 23 cases (22.5%). According to the differentiation stage of tumors (grade), samples were classified as, well differentiated (low grade), moderately differentiated (intermediate grade) and poorly differentiated (high grade), corresponding to 8 (7.8%), 74 (72,5%) and 20 (19.6%) patients, respectively. All patients were followed-up for 2 to 68 months, (mean 38.3±16.7 months) and the median follow-up time for all patients was 38 months.

E and D1 cyclin expression in colon cancer patients. Sections were evaluated as either “positive” for cyclin D1, p21 or pRb when the majority of the cells in the selected sections were positively stained compared to the control, normal colon tissue, negative for cyclin D1. Five percent (5%) was used as the cutoff value as previously published (39-42). For cyclin E and Ki-67, we defined labeling index (LI) (%) as the percentage of tumor cells which displayed nuclear immunoreactivity. Overall, 64.7% and 50% of tissue samples from colon cancer patients were found positive for cyclin D1 and E (Figure 1), respectively. In 22.7% of cases, cyclin D1 expression was nuclear, 4.5% cytoplasmic and 72.7% mixed (cytoplasmic and nuclear localization of cyclin D1). All samples positive for cyclin E expression revealed a high level of expression (LI≥30%), while D1 immunostaining was evaluated as low in 32 out of the 66 cases (48.5%), moderate in 24 out of 66 (36.4%), and high in 10 out of 66 (15.1%). However, when the pattern and the intensity of cyclin D1 were compared to tumor or patient characteristics (Table I), no correlation was observed. Moreover, no significant association of the cyclin D1 pattern was observed when compared with the Rb expression.

We further analyzed patient's colon cancers for p21 expression. A total of 48 patients (47%) presented a positive staining, however, no significant association between p21 expression and TNM classification, survival rate or Rb protein expression was detected (Table I). Nevertheless, cyclin E expression was correlated with cyclin D1 (p=0.038), p21 (p=0.047), and Rb expression (p=0.004) (Table II). Among the 64 cases of tumors with cyclin D1 positive staining, 38 of them expressed cyclin E at high levels. Similarly, among the 48 cases with p21 positive tumors, 29 highly expressed cyclin E.

The intensity of pRb staining (Figure 2) was assessed as low in 27 out of 64 (42.2%), as moderate in 18 out of 64 (28.1%) and as high in 19 out of 64 cases (29.7%). Among the 38 cases of tumors with pRb negative staining, 17 of them were cyclin D1 negative, however this was not statistically significant. However, no relation between pRb expression and age, tumor location, histological stage, grade, lymph node, liver metastasis and venous invasion was detected.

Follow-up of the patients did not show any effect of cyclin D1, cyclin E and pRb on the 5-year survival rate. Patients with advanced stage disease (stage III and IV) and positive for cyclin D1 were found to have significantly poorer survival rates compared those with a negative cyclin D1 expression (p=0.009). In addition, the survival of patients who were less than 70 years old, was significantly correlated with a positive cyclin D1 expression (p=0.008).

To determine the proliferative capacity of colon cancer cases with abnormal expression of Rb, p21 and cyclins E and D1, we performed immunostaining for Ki-67 (Table III). We observed a statistically significant association between tumor proliferative capacity expressed as Ki-67 labeling index (LI) and positive cyclin D1 staining (p=0.009), positive pRb staining (p=0.031), and positive p21 staining (p=0.050). Tumors with low levels of cyclin E expression presented higher Ki-67 LI compared to tumors with high levels of cyclin E (p=0.322).

Among the 66 tumors positive for cyclin D1 expression, 38 were assessed to have less than 30% Ki-67 positive cells, and 38 had ≥30%. Among the 64 patients presenting Rb positive tumors, 36 were assessed to have more than 30% Ki-67 positive cells, and 28 had less than 30% (p=0.031), (Table III).

Discussion

In the present study, we have demonstrated the different expression patterns of cyclin D1 and cyclin E in the cell proliferation and clinical outcome of colon cancer. Cyclin D1 expression was positively correlated with cell growth as determined by Ki-67 expression. However, it was not an independent unfavorable prognostic factor. On the other hand, cyclin E expression was not associated neither with the Ki-67 LI nor with clinical outcome. Our study showed that cyclin D1 expression is involved in cell growth and is highly expressed in young colon cancer patients with advanced stage disease, suggesting that it may have a great value in identifying high-risk colon cancer patients. Similarly, in a cohort study of 602 colon cancer cases, cyclin D1 overexpression was associated with a low cancer-specific mortality in Kaplan–Meier analysis (p=0.006) or in other words with longer survival (43).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Expression of cyclin E in colon cancer patients' samples and correlation with cyclin D1, p21 and pRb expression.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Cyclin E, cyclin D1, pRb and p21 and their correlation with Ki-67 in colon cancer.

Cyclin E, p21 and Rp protein accumulation were not of any significant prognostic value. Cyclin E expression and the cellular marker of proliferation Ki67 have been shown to be positively correlated. On the contrary, p27kip1 protein expression and Ki67 were negatively correlated.

These results were closely related to the TNM stage and degree of differentiation. Peculiarly, these results were also associated with prognosis, progression-free survival and median survival.

Although these observations emphasize the importance of cyclins in tumorigenesis and prognosis, the question remains and further studies are needed to further evaluate the role of cyclins on the onset of colon cancer or other malignancies. In conclusion, cyclins can be used as sensitive and accurate markers for the diagnosis of colorectal cancer (37).

Acknowledgements

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Footnotes

  • Authors' Contributions

    PP, GK, DC: conception and design of the study; PP, DC: acquisition of data, drafting the article; ST: histological study, analysis of histological scores; GK, DC: drafting the article, revising it critically for important intellectual content; GK: final approval of the version to be submitted.

  • Conflicts of Interest

    The Authors declare no conflicts of interest regarding this study.

  • Received July 8, 2019.
  • Revision received September 21, 2019.
  • Accepted September 23, 2019.
  • Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Marley AR,
    2. Nan H
    : Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet 7(3): 105-114, 2016. PMID: 27766137.
    OpenUrlPubMed
  2. ↵
    1. Barchitta M,
    2. Maugeri A,
    3. Destri GL,
    4. Basile G,
    5. Agodi A
    : Epigenetic biomarkers in colorectal cancer patients receiving adjuvant or neoadjuvant therapy: A systematic review of epidemiological studies. Int J Mol Sci 20(15), 2019. PMID: 31390840. DOI: 10.3390/ijms20153842
  3. ↵
    GLOBOCAN 2018 Graph production. Available at: http://gco.iarc.fr/today/online-analysis-map?v=2018&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=5&group_cancer=1&include_nmsc=1&include_nmsc_other=1&projection=natural-earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&rotate=%255B10%252C0%255D
  4. ↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    : Cancer statistics, 2019. CA Cancer J Clin 69(1): 7-34, 2019. PMID: 30620402. DOI: 10.3322/caac.21551
    OpenUrlCrossRefPubMed
  5. ↵
    1. Yamashita K,
    2. Matsuda T,
    3. Hasegawa H,
    4. Mukohyama J,
    5. Arimoto A,
    6. Tanaka T,
    7. Yamamoto M,
    8. Matsuda Y,
    9. Kanaji S,
    10. Nakamura T,
    11. Sumi Y,
    12. Suzuki S,
    13. Kakeji Y
    : Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives. Ann Gastroenterol Surg 3(1): 24-33, 2019. PMID: 30697607. DOI: 10.1002/ags3.12213
    OpenUrlPubMed
  6. ↵
    1. Malumbres M,
    2. Barbacid M
    : Mammalian cyclin-dependent kinases. Trends Biochem Sci 30(11): 630-641, 2005. PMID: 16236519. DOI: 10.1016/j.tibs.2005.09.005
    OpenUrlCrossRefPubMed
  7. ↵
    1. Fernandez-Guerra A,
    2. Aze A,
    3. Morales J,
    4. Mulner-Lorillon O,
    5. Cosson B,
    6. Cormier P,
    7. Bradham C,
    8. Adams N,
    9. Robertson AJ,
    10. Marzluff WF,
    11. Coffman JA,
    12. Genevière AM
    : The genomic repertoire for cell cycle control and DNA metabolism in S. purpuratus. Dev Biol 300(1): 238-251, 2006. PMID: 17078944. DOI: 10.1016/j.ydbio.2006.09.012
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ye X,
    2. Wei Y,
    3. Nalepa G,
    4. Harper JW
    : The cyclin E/Cdk2 substrate p220(NPAT) is required for S-phase entry, histone gene expression, and Cajal body maintenance in human somatic cells. Mol Cell Biol 23(23): 8586-8600, 2003. PMID: 14612403. DOI: 10.1128/mcb.23.23.8586-8600.2003
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Siemeister G,
    2. Lucking U,
    3. Wengner AM,
    4. Lienau P,
    5. Steinke W,
    6. Schatz C,
    7. Mumberg D,
    8. Ziegelbauer K
    : BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol Cancer Ther 11(10): 2265-2273, 2012. PMID: 22821149. DOI: 10.1158/1535-7163.MCT-12-0286
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Johnson A,
    2. Skotheim JM
    : Start and the restriction point. Curr Opin Cell Biol 25(6): 717-723, 2013. PMID: 23916770. DOI: 10.1016/j.ceb.2013.07.010
    OpenUrlCrossRefPubMed
  11. ↵
    1. Bertoli C,
    2. Skotheim JM,
    3. de Bruin RA
    : Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol 14(8): 518-528, 2013. PMID: 23877564. DOI: 10.1038/nrm3629
    OpenUrlCrossRefPubMed
  12. ↵
    1. Massague J
    : G1 cell-cycle control and cancer. Nature 432(7015): 298-306, 2004. PMID: 15549091. DOI: 10.1038/nature03094
    OpenUrlCrossRefPubMed
  13. ↵
    1. Resnitzky D,
    2. Reed SI
    : Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol 15(7): 3463-3469, 1995. PMID: 7791752. DOI: 10.1128/mcb.15.7.3463
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Keyomarsi K,
    2. Pardee AB
    : Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90(3): 1112-1116, 1993. PMID: 8430082. DOI: 10.1073/pnas. 90.3.1112
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Buckley MF,
    2. Sweeney KJ,
    3. Hamilton JA,
    4. Sini RL,
    5. Manning DL,
    6. Nicholson RI,
    7. deFazio A,
    8. Watts CK,
    9. Musgrove EA,
    10. Sutherland RL
    : Expression and amplification of cyclin genes in human breast cancer. Oncogene 8(8): 2127-2133, 1993. PMID: 8336939.
    OpenUrlPubMed
  16. ↵
    1. Kitahara K,
    2. Yasui W,
    3. Kuniyasu H,
    4. Yokozaki H,
    5. Akama Y,
    6. Yunotani S,
    7. Hisatsugu T,
    8. Tahara E
    : Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 62(1): 25-28, 1995. PMID: 7601562. DOI: 10.1002/ijc.2910620107
    OpenUrlCrossRefPubMed
  17. ↵
    1. Keyomarsi K,
    2. O'Leary N,
    3. Molnar G,
    4. Lees E,
    5. Fingert HJ,
    6. Pardee AB
    : Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54(2): 380-385, 1994. PMID: 7903908.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Wiman KG
    : The retinoblastoma gene: role in cell cycle control and cell differentiation. FASEB J 7(10): 841-845, 1993. PMID: 8393817. DOI: 10.1096/fasebj.7.10.8393817
    OpenUrlPubMed
  19. ↵
    1. Bartek J,
    2. Lukas J,
    3. Strauss M
    : A common path to tumor growth. Oncol Rep 3(2): 237-240, 1996. PMID: 21594350. DOI: 10.3892/or.3.2.237
    OpenUrlPubMed
  20. ↵
    1. Sherr CJ
    : Cancer cell cycles. Science 274(5293): 1672-1677, 1996. PMID: 8939849. DOI: 10.1126/science.274.5293.1672
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Harper JW,
    2. Adami GR,
    3. Wei N,
    4. Keyomarsi K,
    5. Elledge SJ
    : The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75(4): 805-816, 1993. PMID: 8242751. DOI: 10.1016/0092-8674(93)90499-g
    OpenUrlCrossRefPubMed
  22. ↵
    1. Muller H,
    2. Lukas J,
    3. Schneider A,
    4. Warthoe P,
    5. Bartek J,
    6. Eilers M,
    7. Strauss M
    : Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci USA 91(8): 2945-2949, 1994. PMID: 8159685. DOI: 10.1073/pnas.91.8.2945
    OpenUrlAbstract/FREE Full Text
    1. Yu B,
    2. Lane ME,
    3. Pestell RG,
    4. Albanese C,
    5. Wadler S
    : Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein. Mol Cell Biol Res Commun 3(6): 352-359, 2000. PMID: 11032757. DOI: 10.1006/mcbr.2000.0238
    OpenUrlCrossRefPubMed
  23. ↵
    1. Geng Y,
    2. Eaton EN,
    3. Picon M,
    4. Roberts JM,
    5. Lundberg AS,
    6. Gifford A,
    7. Sardet C,
    8. Weinberg RA
    : Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12(6): 1173-1180, 1996. PMID: 8649818.
    OpenUrlPubMed
  24. ↵
    1. Venter DJ,
    2. Bevan KL,
    3. Ludwig RL,
    4. Riley TE,
    5. Jat PS,
    6. Thomas DG,
    7. Noble MD
    : Retinoblastoma gene deletions in human glioblastomas. Oncogene 6(3): 445-448, 1991. PMID: 2011399.
    OpenUrlPubMed
  25. ↵
    1. Bookstein R,
    2. Shew JY,
    3. Chen PL,
    4. Scully P,
    5. Lee WH
    : Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247(4943): 712-715, 1990. PMID: 2300823. DOI: 10.1126/science.2300823
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Chetty R,
    2. Subramoney T,
    3. Singh J,
    4. Harilal P
    : Retinoblastoma (pRb) protein immunoexpression in colorectal cancer. Anticancer Res 17(4A): 2593-2597, 1997. PMID: 9252686.
    OpenUrlPubMed
  27. ↵
    1. Gope R,
    2. Christensen MA,
    3. Thorson A,
    4. Lynch HT,
    5. Smyrk T,
    6. Hodgson C,
    7. Wildrick DM,
    8. Gope ML,
    9. Boman BM
    : Increased expression of the retinoblastoma gene in human colorectal carcinomas relative to normal colonic mucosa. J Natl Cancer Inst 82(4): 310-314, 1990. PMID: 2405172. DOI: 10.1093/jnci/82.4.310
    OpenUrlCrossRefPubMed
  28. ↵
    1. Meling GI,
    2. Lothe RA,
    3. Borresen AL,
    4. Hauge S,
    5. Graue C,
    6. Clausen OP,
    7. Rognum TO
    : Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis. Br J Cancer 64(3): 475-480, 1991. PMID: 1911187. DOI: 10.1038/bjc.1991.334
    OpenUrlPubMed
  29. ↵
    1. Ohtsubo M,
    2. Theodoras AM,
    3. Schumacher J,
    4. Roberts JM,
    5. Pagano M
    : Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15(5): 2612-2624, 1995. PMID: 7739542. DOI: 10.1128/mcb.15.5.2612
    OpenUrlAbstract/FREE Full Text
    1. Baldin V,
    2. Lukas J,
    3. Marcote MJ,
    4. Pagano M,
    5. Draetta G
    : Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7(5): 812-821, 1993. PMID: 8491378. DOI: 10.1101/gad.7.5.812
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Quelle DE,
    2. Ashmun RA,
    3. Shurtleff SA,
    4. Kato JY,
    5. Bar-Sagi D,
    6. Roussel MF,
    7. Sherr CJ
    : Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7(8): 1559-1571, 1993. PMID: 8339933. DOI: 10.1101/gad.7.8.1559
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Mermelshtein A,
    2. Gerson A,
    3. Walfisch S,
    4. Delgado B,
    5. Shechter-Maor G,
    6. Delgado J,
    7. Fich A,
    8. Gheber L
    : Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer 93(3): 338-345, 2005. PMID: 16012517. DOI: 10.1038/sj.bjc.6602709
    OpenUrlCrossRefPubMed
  32. ↵
    1. Wangefjord S,
    2. Manjer J,
    3. Gaber A,
    4. Nodin B,
    5. Eberhard J,
    6. Jirstrom K
    : Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study. Biol Sex Differ 2: 10, 2011. PMID: 21888663. DOI: 10.1186/2042-6410-2-10
    OpenUrlPubMed
  33. ↵
    1. Li Y,
    2. Wei J,
    3. Xu C,
    4. Zhao Z,
    5. You T
    : Prognostic significance of cyclin D1 expression in colorectal cancer: a meta-analysis of observational studies. PLoS One 9(4): e94508, 2014. PMID: 24728073. DOI: 10.1371/journal.pone.0094508
    OpenUrlCrossRefPubMed
  34. ↵
    1. Al-Maghrabi J,
    2. Mufti S,
    3. Gomaa W,
    4. Buhmeida A,
    5. Al-Qahtani M,
    6. Al-Ahwal M
    : Immunoexpression of cyclin D1 in colorectal carcinomas is not correlated with survival outcome. J Microsc Ultrastruct 3(2): 62-67, 2015. PMID: 30023183. DOI: 10.1016/j.jmau.2015.01.001
    OpenUrlPubMed
  35. ↵
    1. Li W,
    2. Zhang G,
    3. Wang HL,
    4. Wang L
    : Analysis of expression of cyclin E, p27kip1 and Ki67 protein in colorectal cancer tissues and its value for diagnosis, treatment and prognosis of disease. Eur Rev Med Pharmacol Sci 20(23): 4874-4879, 2016. PMID: 27981549.
    OpenUrlPubMed
  36. ↵
    1. Fischer AH,
    2. Jacobson KA,
    3. Rose J,
    4. Zeller R
    : Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc 2008: pdb prot4986, 2008. PMID: 21356829. DOI: 10.1101/pdb.prot4986
  37. ↵
    1. Michalides R,
    2. Hageman P,
    3. van Tinteren H,
    4. Houben L,
    5. Wientjens E,
    6. Klompmaker R,
    7. Peterse J
    : A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73(6): 728-734, 1996. PMID: 8611372. DOI: 10.1038/bjc.1996.128
    OpenUrlCrossRefPubMed
    1. Palmqvist R,
    2. Stenling R,
    3. Oberg A,
    4. Landberg G
    : Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. Eur J Cancer 34(10): 1575-1581, 1998. PMID: 9893631. DOI: 10.1016/s0959-8049(98)00162-2
    OpenUrlCrossRefPubMed
    1. Maeda K,
    2. Chung Y,
    3. Kang S,
    4. Ogawa M,
    5. Onoda N,
    6. Nishiguchi Y,
    7. Ikehara T,
    8. Nakata B,
    9. Okuno M,
    10. Sowa M
    : Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology 55(2): 145-151, 1998. PMID: 9499189. DOI: 10.1159/000011849
    OpenUrlCrossRefPubMed
  38. ↵
    1. Michalides R,
    2. van Veelen N,
    3. Hart A,
    4. Loftus B,
    5. Wientjens E,
    6. Balm A
    : Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55(5): 975-978, 1995. PMID: 7867006.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Ogino S,
    2. Nosho K,
    3. Irahara N,
    4. Kure S,
    5. Shima K,
    6. Baba Y,
    7. Toyoda S,
    8. Chen L,
    9. Giovannucci EL,
    10. Meyerhardt JA,
    11. Fuchs CS
    : A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res 15(13): 4431-4438, 2009. PMID: 19549773. DOI: 10.1158/1078-0432.CCR-08-3330
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 39 (11)
Anticancer Research
Vol. 39, Issue 11
November 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Prognostic Value of G1 Cyclins, p21 and Rb Protein in Patients With Colon Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The Prognostic Value of G1 Cyclins, p21 and Rb Protein in Patients With Colon Cancer
PANTELIS PALAIOLOGOS, DIMOSTHENIS CHRYSIKOS, STAMATIOS THEOCHARIS, GREGORY KOURAKLIS
Anticancer Research Nov 2019, 39 (11) 6291-6297; DOI: 10.21873/anticanres.13839

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
The Prognostic Value of G1 Cyclins, p21 and Rb Protein in Patients With Colon Cancer
PANTELIS PALAIOLOGOS, DIMOSTHENIS CHRYSIKOS, STAMATIOS THEOCHARIS, GREGORY KOURAKLIS
Anticancer Research Nov 2019, 39 (11) 6291-6297; DOI: 10.21873/anticanres.13839
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A
  • Google Scholar

More in this TOC Section

  • Tumor Budding Grade and T Stage as Recurrence Predictors of High-risk Stage II Colorectal Cancer
  • Pathologic Complete Response (pCR) in Patient With Myxofibrosarcoma Who Underwent Neoadjuvant Radiation Concurrent to Complementary and Alternative Medicine
  • Machine Learning Model to Guide Empirical Antimicrobial Therapy in Febrile Neutropenic Patients With Hematologic Malignancies
Show more Clinical Studies

Similar Articles

Keywords

  • Cyclin D1
  • Cyclin E
  • Rb
  • p21
  • prognosis
  • colon cancer
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire